Are We FULFIL-led by a Once-daily Triple-therapy Inhaler for Chronic Obstructive Pulmonary Disease?


    loading  Checking for direct PDF access through Ovid

Abstract

Synopsis: A once-daily triple-therapy inhaler, consisting of a long-acting muscarinic antagonist, a long-acting beta agonist, and an inhaled corticosteroid, resulted in significant improvements in lung function and quality of life in patients with severe chronic obstructive pulmonary disease when compared with a twice-daily dual-therapy inhaler, consisting of a long-acting beta agonist and an inhaled corticosteroid.Source: Lipson D, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196(4):438–446.

    loading  Loading Related Articles